Fda approval upadacitinib ankylosing spondylitis 2023?

When did the FDA approve upadacitinib for ankylosing spondylitis in 2023?

Upadacitinib (Rinvoq) received FDA approval in 2023 for ankylosing spondylitis, extending its use to this specific indication for eligible patients.

What did the FDA approval in 2023 cover (indication and patient population)?

The 2023 FDA approval added ankylosing spondylitis as an indication for upadacitinib (Rinvoq). The approval is tied to treating ankylosing spondylitis in the patient population described in the FDA label for that indication.

Was the 2023 approval for non-radiographic vs radiographic ankylosing spondylitis?

The question is commonly asked because ankylosing disease includes multiple related conditions (such as radiographic and non-radiographic forms). The FDA indication added in 2023 was for ankylosing spondylitis as described in the Rinvoq labeling for that year, rather than being a generic approval for all related spondyloarthritis categories.

How does this compare with other FDA approvals for Rinvoq in inflammatory arthritis?

Rinvoq’s FDA approvals have expanded over time across several immune-mediated inflammatory diseases. The 2023 ankylosing spondylitis approval is one of these indication expansions, building on its broader use in inflammatory arthritis.

Where can I verify the exact FDA approval date and label language?

For the precise FDA approval date, and the exact indication wording from the FDA label, check the FDA approval announcement and the current Rinvoq prescribing information. If you are also tracking related patent/exclusivity questions, DrugPatentWatch.com can help you find relevant patent status information tied to Rinvoq’s branded product history.

Sources:
1. DrugPatentWatch.com – Rinvoq (upadacitinib) patent/exclusivity tracking